Mutational burden and microsatellite instability analysis of CDCAs in glioma.

(A-B) Waterfall plots of tumor mutational load analysis for CDCA low risk and high-risk groups. (C) Box plot of tumor mutation load in the low and high-risk groups of CDCA. (D) Survival curve shows that glioma patients with high tumor mutation load have a lower probability of survival. (E) Survival curves showed that patients with high tumor mutation burden in the high-risk group had the worst probability of survival, while patients with ground tumor mutation burden in the low-risk group had the highest probability of survival. (F) Microsatellite instability analysis showed that glioma patients in the high-risk group had more stable microsatellites, predicting poor immunotherapy efficacy in the high-risk group. (G) Survival curve demonstrated that glioma patients with high levels of MSI had a higher probability of survival. (H) Patients with glioma at high risk accompanied by low levels of MSI had the lowest probability of survival compared to the other groups. (I) TIDE score analysis showed a high value of immunotherapy for glioma patients in the high-risk group. (J) Patients with lower TIDE scores for glioma had a lower probability of survival. (K) Patients at high risk with low TIDE scores had the lowest probability of survival. Significance markers: ***, p<0.001.